Palliative Care: Dyspnea and Breakthrough Pain

Journal of Pharmaceutical Care in Pain and Symptom Control

Volumn 9, Issue 4, 2001, Pages 73-78

  Fine, Perry G ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VistaCare   (United States)

Author keywords

air hunger; breakthrough pain; breathlessness; Dyspnea; end of dose failure; end of life care; incident pain; nebulized opioid; palliative care

Indexed keywords

EID: 2542479546     PISSN: 10564950     EISSN: None     Source Type: Journal    
DOI: 10.1300/J088v09n04_07     Document Type: Article

References (10)

1. Ripamonti C, Dyspnea Bruera B. Pathophysiology and assessment. J Pain Sympt Manage 1997; 13: 220 – 232
2. Farncombe M, et al. The use of nebulized opioids for breathlessness. Palliative Medicine 1994; 8: 306 – 312
3. Portenoy R K, Hagen N A. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273 – 281
4. Fine P G, Busch M. Characterization of breakthrough pains by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179 – 183
5. Ashburn M A, Fine P G, Stanley T H. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain. Anesthesiology 1989; 71: 615 – 617
6. Fine P G, Marcus M, DeBoer A J, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45: 149 – 153
7. Simmonds M A. 1997, Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting
8. Lyss A P. 1997, Long-term use of oral transmucosal fentanyl citrate (OTFC) for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting
9. Coluzzi P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients. American Society of Clinical Oncology (ASCO) Annual Meeting. 1997
10. Cleary J F. Double-blind randomized study of the treatment of breakthrough pain in cancer patients: Oral transmucosal fentanyl citrate vs. placebo. American Society of Clinical Oncology (ASCO). 1997, Annual Meeting